CP
BIIB icon

Camelot Portfolios’s Biogen BIIB Stock Holding History

Camelot Portfolios’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$8K – 246
2021
Q1 		$8K Buy
+200
New +$53.9K ﹤0.01% 217

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Camelot Portfolios's BIIB Position: Q2 2026 in Review

Camelot Portfolios held its Biogen (BIIB) position steady in Q2 2026 at 1,900 shares worth $411K. The position accounts for 0.29% of the portfolio, ranked #126.

Camelot Portfolios first reported a position in BIIB in Q2 2018 and has held it in 28 quarters since. The position peaked at $1.59M in Q4 2019. 569 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Camelot Portfolios held 1,900 shares of Biogen worth $411K as of Q2 2026.
  • Camelot Portfolios left its Biogen share count unchanged in Q2 2026.
  • Biogen made up 0.29% of Camelot Portfolios's portfolio in Q2 2026, its #126 holding.
  • Camelot Portfolios first reported a position in Biogen in Q2 2018 and has held it in 28 quarters since.
  • Camelot Portfolios's Biogen position peaked at $1.59M in Q4 2019.
  • 569 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Camelot Portfolios's 13F filing for Q2 2026, filed 17 Jul 2026.